articles
Exploring Plant-Based Bioreactors for Developing COVID-19 Therapeutics and Vaccines
Biologics company iBio, is focused on developing therapeutics and vaccines using a novel plant-based system. It recently announced a worldwide licensing agreement with Planet Biotech to develop ...
articles
The Advantages of Implementing Plant-Based Vaccines
Accelerated development of vaccines is essential to public health and pandemic preparedness, both for the current COVID-19 pandemic and future threats. iBio is developing multiple vaccine ...
articles
iBio’s FastPharming® Platform Produces Decoy Therapeutic to Bind to SARS-CoV-2
iBio, Inc. is developing a decoy molecule as a therapeutic against SARS-CoV-2. Recently licensed from Planet Biotechnology, the candidate is a recombinant protein made from human angiotensin ...
articles
Applying Rapid Countermeasure Preparedness to Development of a Novel COVID-19 Vaccine
The COVID-19 pandemic sweeping across the globe is pushing innovation to the cutting edge throughout the biopharma industry. More rapid development of novel diagnostics, therapeutics, and ...
articles
Fast-Farming Pharma: How plants could speed up vaccine manufacture to tackle the COVID-19 pandemic
At the start of April 2020, the global number of confirmed COVID-19 cases was rapidly approaching 1.5 million; the death toll: over 80,000. And these numbers will likely have changed ...
articles
Rapid Delivery of Medical Countermeasures Amid Pandemic
Immeasurable efforts are underway to develop treatments and vaccines to address the COVID-19 pandemic. Numerous discovery methods and technologies are currently being explored in clinical trials ...
articles
Building Therapeutic Proteins through Plant Glycosylation: A Sweet Solution
N-Glycosylation is a critical component of many protein-based therapeutics, required for appropriate stability, immunogenicity, and pharmacokinetics. In addition, it is essential for key ...
articles
iBio’s transformation driven by FastPharming System, 3D bioprinting materials and proprietary therapeutics
iBio (NYSE American:IBIO) is continuing its transition from a licensing business to a manufacturing services provider and developer of proprietary biologics. Central to the initiative is a new ...
articles
Facilitating 3D Organ Printing with Plant-Based BioInks
There is a chronic shortage of organs available for transplant. Bioprinted organs could dramatically increase accessibility to all patients in need of transplants. Some simpler biofabricated ...
articles
Successfully Addressing the Challenges of Glycosylation
Post-translational modification is a critical step in the synthesis of biotherapeutic molecules. Among these alterations to the original naked protein, glycosylation may be the most significant ...
articles
Reducing Fill-Finish Wait Times
iBio has expanded its CDMO service offerings to include independent sterile liquid cGMP fill-finish services to support the preclinical and clinical trial needs of drug developers. This new ...
articles
The Advantage of Plant-based Expression Solutions Around the Globe
iBio offers development and manufacturing services for biologic drug substances and drug products, built around our proprietary plant-based platform technology. Client support is offered from ...
articles
Plant-Based Protein Expression for Rapid, Green Bioprocessing
Mammalian cell culture is widely used for biologic drug substance production, but the high cost and long development times pose challenges to the implementation of this technology in many parts ...
articles
Divine Outsourcing Model for Biotechs
Imagine you work at a virtual biopharma with a highly specialized biopharmaceutical ready for advanced development. You contact the one CDMO that you’ve been told undoubtedly has the most ...
articles
Build Biologics Not Barriers
The current trade conflict between the world's biggest economies — the United States and China — has resulted in both countries imposing billions of dollars’ worth of tariffs on each other’s ...
articles
CMOs on Fire
Recently, contract manufacturers have taken the conventional definition of outsourcing, and set it on fire. Traditionally, CMOs provided capacity reservoirs for pharma companies to tap as ...
articles
CDMO Outsourcing Trends
Outsourcing to Contract Development and Manufacturing Organizations (CDMOs) has been on the rise, driven by increasingly complex drug candidates and the expertise they require, and now, ...
articles
In Vivo Glycan Engineering Via the Mannosidase I Inhibitor (Kifunenesine) Improves Efficacy of Rituximab Manufacture in Nicotiana benthamiana Plants
Monoclonal antibodies (mAbs) represent the fastest growing class of therapeutics [1,2] and have been especially beneficial in the treatment of cancer [3]. Since the approval of the first ...
articles
Plant Derived Rituximab? iBio Inks "Green" Bioreactor Tech Deal in China
According to the agreement, Delaware, US-based iBio will provide process development and manufacturing services at its Texas facility, and will assist CC-Pharming in preparing a site for ...
articles
Plant-Made E2 Glycoprotein Single-Dose Vaccine Protects Pigs against Classical Swine Fever
Introduction Classical Swine Fever (CSF) is a highly contagious hemorrhagic disease affecting pigs. CSF outbreaks have caused substantial economic damages to the swine industry worldwide, ...
articles
Implementation of Glycan Remodeling to Plant-Made Therapeutic Antibodies
Introduction Therapeutic glycoproteins represent a predominant disease treatment category among biopharmaceuticals approved or in clinical development. N-linked glycosylation is a very important ...
articles
AzarGen Biotechnologies Granted European Patent for Plant-Made Production of Recombinant Human Surfactant Protein-B
AzarGen Biotechnologies (Pty) Ltd (Stellenbosch, South Africa), announced that it has received grant status for the patent application: PRODUCTION OF HUMAN PULMONARY SURFACTANT PROTEIN-B IN ...
articles
U.S. Patent Granted to AzarGen Biotechnologies for Synthetic Promoter Technology
AzarGen Biotechnologies (Pty) Ltd (Stellenbosch, South Africa) announced that it has received grant status for the patent application: SYNTHETIC PROMOTER CONSTRUCT FOR TRANSGENE EXPRESSION ...
articles
AzarGen's Case for a Commercial Plant-Made Pharmaceutical Facility in South Africa
AzarGen Biotechnologies, South Africa’s only private plant-based biopharmaceutical company, is imagining a world-class commercial plant-made pharmaceutical facility for South Africa.
articles
Planting the Seed for Speed
You probably won’t find a lot of presidents of successful contract manufacturing organizations gleefully operating the forklift inside the manufacturing plant, but Barry Holtz is no ordinary ...
articles
Techno-Economic Analysis of a Transient Plant-Based Platform for Monoclonal Antibody Production
Introduction Since the commercialization of the first therapeutic monoclonal antibody (mAb) in 1986, this class of biopharmaceutical products has grown exponentially. As of November 2014, ...
articles
Commercial-Scale Biotherapeutics Manufacturing Facility for Plant-Made Pharmaceuticals
Introduction In recent years, the plant‐made pharmaceutical (PMP) community has made significant progress in bringing therapeutics to the clinic: Elelyso™ (Pastores et al., 2014; ...
